GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

Registration

Registration

NCT01592279

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE4

Masking

DOUBLE

Status

UNKNOWN

Enrollment

124

Start

2012-06

Primary completion

2014-06

Lead sponsor

Hadassah Medical Organization

Conditions

Uncontrolled Type 1 Diabetic Patients

Interventions

DRUG:liraglutide; DRUG:Insulin injections

Results posted

FALSE

Registered primary outcomes

• The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline. [the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients.]